Diagnostic value of combined detection of carbohydrate antigen 125 and human epididymis protein 4 for epithelial ovarian cancer

Q4 Medicine
Meng Tong, Lixin Sun
{"title":"Diagnostic value of combined detection of carbohydrate antigen 125 and human epididymis protein 4 for epithelial ovarian cancer","authors":"Meng Tong, Lixin Sun","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.002","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the diagnostic value of combined detection of serum human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) for ovarian epithelial cancer. \n \n \nMethods \nPatients who underwent surgery for the adnexal tumor at Shanxi Provincial Cancer Hospital from January 2012 to December 2017 were enrolled. According to the postoperative pathological results, these patients were divided into the ovarian epithelial cancer group (494 cases) and benign ovarian disease group (462 cases). The serum expressions of HE4 and CA125 in the two groups were detected by enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay. The diagnostic value of detection of HE4 and CA125 alone or in combination for ovarian epithelial cancer was analyzed. \n \n \nResults \nThe median levels (P 25 - P 75) of serum CA125 and HE4 in ovarian epithelial cancer group were 273.34 U/ml (39.34 U/ml, 709.74 U/ml) and 199.08 pmol/L (75.81 pmol/L, 449.20 pmol/L), which were higher than those in ovarian benign disease group [16.30 U/ml (6.30 U/ml, 53.60 U/ml) and 39.54 pmol/L (29.57 pmol/L, 53.80 pmol/L)] (both P < 0.05). There was a positive correlation between serum CA125 and HE4 levels in ovarian epithelial cancer group (r = 0.481, P < 0.01). Serum CA125 and HE4 levels in patients with stage Ⅲ and Ⅳ were higher than those in patients with stage Ⅰ and Ⅱ (both P < 0.05), and serum CA125 and HE4 levels in patients with poor differentiation were higher than those in patients with moderate differentiation (P < 0.05). Compared with CA125, the specificity and positive predictive value of serum HE4 for the diagnosis of ovarian epithelial cancer were higher (both P < 0.01). Compared with HE4 alone, the sensitivity of CA125 combined with HE4 increased (P = 0.004) and the specificity decreased (P = 0.044). When both CA125 and HE4 were positive for positive results, compared with HE4 alone, the specificity and positive predictive value increased (both P < 0.01), but the sensitivity decreased (both P < 0.01). In patients with CA125+ HE4-, the sensitivity and specificity decreased, while in CA125- HE4+ patients, the specificity was elevated, but the difference was not statistically significant (P = 0.892). When one of CA125 and HE4 was positive for positive results, the sensitivity and negative predictive value increased (both P < 0.01), but the specificity and positive predictive value decreased (both P < 0.01). The area under the curve of serum CA125 and HE4 combined detection was 0.911, indicating its clinical diagnostic value was better than that of the two alone. \n \n \nConclusions \nIn the diagnosis of epithelial ovarian cancer, the specificity of serum HE4 is higher than that of CA125, but the sensitivity is lower than that of CA125. The combined detection of HE4 and CA125 is more conducive to improve the diagnostic accuracy of ovarian epithelial cancer. \n \n \nKey words: \nOvarian neoplasms; Carbohydrate antigen 125; Human epididymis protein 4; Diagnosis","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"31 1","pages":"653-657"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To explore the diagnostic value of combined detection of serum human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) for ovarian epithelial cancer. Methods Patients who underwent surgery for the adnexal tumor at Shanxi Provincial Cancer Hospital from January 2012 to December 2017 were enrolled. According to the postoperative pathological results, these patients were divided into the ovarian epithelial cancer group (494 cases) and benign ovarian disease group (462 cases). The serum expressions of HE4 and CA125 in the two groups were detected by enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay. The diagnostic value of detection of HE4 and CA125 alone or in combination for ovarian epithelial cancer was analyzed. Results The median levels (P 25 - P 75) of serum CA125 and HE4 in ovarian epithelial cancer group were 273.34 U/ml (39.34 U/ml, 709.74 U/ml) and 199.08 pmol/L (75.81 pmol/L, 449.20 pmol/L), which were higher than those in ovarian benign disease group [16.30 U/ml (6.30 U/ml, 53.60 U/ml) and 39.54 pmol/L (29.57 pmol/L, 53.80 pmol/L)] (both P < 0.05). There was a positive correlation between serum CA125 and HE4 levels in ovarian epithelial cancer group (r = 0.481, P < 0.01). Serum CA125 and HE4 levels in patients with stage Ⅲ and Ⅳ were higher than those in patients with stage Ⅰ and Ⅱ (both P < 0.05), and serum CA125 and HE4 levels in patients with poor differentiation were higher than those in patients with moderate differentiation (P < 0.05). Compared with CA125, the specificity and positive predictive value of serum HE4 for the diagnosis of ovarian epithelial cancer were higher (both P < 0.01). Compared with HE4 alone, the sensitivity of CA125 combined with HE4 increased (P = 0.004) and the specificity decreased (P = 0.044). When both CA125 and HE4 were positive for positive results, compared with HE4 alone, the specificity and positive predictive value increased (both P < 0.01), but the sensitivity decreased (both P < 0.01). In patients with CA125+ HE4-, the sensitivity and specificity decreased, while in CA125- HE4+ patients, the specificity was elevated, but the difference was not statistically significant (P = 0.892). When one of CA125 and HE4 was positive for positive results, the sensitivity and negative predictive value increased (both P < 0.01), but the specificity and positive predictive value decreased (both P < 0.01). The area under the curve of serum CA125 and HE4 combined detection was 0.911, indicating its clinical diagnostic value was better than that of the two alone. Conclusions In the diagnosis of epithelial ovarian cancer, the specificity of serum HE4 is higher than that of CA125, but the sensitivity is lower than that of CA125. The combined detection of HE4 and CA125 is more conducive to improve the diagnostic accuracy of ovarian epithelial cancer. Key words: Ovarian neoplasms; Carbohydrate antigen 125; Human epididymis protein 4; Diagnosis
碳水化合物抗原125与人附睾蛋白4联合检测对上皮性卵巢癌的诊断价值
目的探讨血清人附睾蛋白4 (HE4)与碳水化合物抗原125 (CA125)联合检测对卵巢癌的诊断价值。方法选取2012年1月至2017年12月在山西省肿瘤医院行附件肿瘤手术的患者为研究对象。根据术后病理结果将患者分为卵巢上皮性癌组(494例)和卵巢良性疾病组(462例)。采用酶联免疫吸附法(ELISA)和化学发光免疫法检测两组患者血清中HE4和CA125的表达。分析HE4、CA125单独或联合检测对卵巢癌的诊断价值。结果卵巢上皮性癌组血清CA125和HE4的中位水平(p25 ~ p75)分别为273.34 U/ml (39.34 U/ml, 709.74 U/ml)和199.08 pmol/L (75.81 pmol/L, 449.20 pmol/L),高于卵巢良性疾病组[16.30 U/ml (6.30 U/ml, 53.60 U/ml)和39.54 pmol/L (29.57 pmol/L, 53.80 pmol/L)] (P < 0.05)。卵巢上皮癌组血清CA125与HE4水平呈正相关(r = 0.481, P < 0.01)。Ⅲ期、Ⅳ期患者血清CA125、HE4水平高于Ⅰ期、Ⅱ期患者(P均< 0.05),差分化期患者血清CA125、HE4水平高于中度分化期患者(P < 0.05)。与CA125相比,血清HE4诊断卵巢上皮性癌的特异性和阳性预测值更高(P < 0.01)。与单独检测HE4相比,CA125联合检测HE4的敏感性升高(P = 0.004),特异性降低(P = 0.044)。当CA125和HE4均为阳性结果时,与单独HE4相比,特异性和阳性预测值升高(P < 0.01),敏感性降低(P < 0.01)。CA125+ HE4-患者敏感性和特异性降低,而CA125- HE4+患者特异性升高,但差异无统计学意义(P = 0.892)。当CA125和HE4其中一项阳性时,敏感性和阴性预测值均升高(P < 0.01),特异性和阳性预测值均降低(P < 0.01)。血清CA125与HE4联合检测曲线下面积为0.911,临床诊断价值优于两者单独检测。结论在诊断上皮性卵巢癌时,血清HE4的特异性高于CA125,但敏感性低于CA125。HE4与CA125联合检测更有利于提高卵巢上皮性癌的诊断准确率。关键词:卵巢肿瘤;碳水化合物抗原125;人附睾蛋白4;诊断
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
肿瘤研究与临床
肿瘤研究与临床 Medicine-Oncology
CiteScore
0.10
自引率
0.00%
发文量
7737
期刊介绍: "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信